BioPorto Cash Flow Conversion Efficiency
BioPorto cash flow conversion efficiency. Based on the latest financial reports, BioPorto (BIOPOR) has a cash flow conversion efficiency ratio of -0.249x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr-15.68 Million ≈ $-2.45 Million USD) by net assets (Dkr63.01 Million ≈ $9.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BioPorto (2000–2025)
Cash flow conversion efficiency of BioPorto from 2000 to 2025. This chart illustrates how BioPorto's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest BioPorto stock price today for real-time trading data and today's change.
BioPorto Cash Flow Conversion Ratio Explained
BioPorto cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BioPorto Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioPorto ranked by their cash flow conversion efficiency. Also see BioPorto market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
|
0.021x |
|
Vascon Engineers Limited
NSE:VASCONEQ
|
-0.063x |
|
HyVision System. Inc
KQ:126700
|
-0.033x |
|
Patriot One Technologies Inc
F:0PL
|
-0.493x |
|
Pierce Group AB
ST:PIERCE
|
-0.026x |
|
Tongyang
KO:001520
|
0.020x |
|
Morn Sun Feed Mill Corp
TWO:1240
|
0.009x |
|
Associated Capital Group Inc
NYSE:AC
|
-0.045x |
Annual Cash Flow Conversion Efficiency for BioPorto (2000–2025)
The table below shows the annual cash flow conversion efficiency of BioPorto from 2000 to 2025. Review BioPorto free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Dkr63.01 Million ≈ $9.86 Million |
Dkr-77.07 Million ≈ $-12.06 Million |
-1.223x | +0.82% |
| 2024-12-31 | Dkr67.78 Million ≈ $10.60 Million |
Dkr-83.58 Million ≈ $-13.08 Million |
-1.233x | -33.78% |
| 2023-12-31 | Dkr60.16 Million ≈ $9.41 Million |
Dkr-55.46 Million ≈ $-8.68 Million |
-0.922x | -23.33% |
| 2022-12-31 | Dkr70.22 Million ≈ $10.99 Million |
Dkr-52.48 Million ≈ $-8.21 Million |
-0.747x | +46.80% |
| 2021-12-31 | Dkr45.96 Million ≈ $7.19 Million |
Dkr-64.58 Million ≈ $-10.10 Million |
-1.405x | -298.07% |
| 2020-12-31 | Dkr100.91 Million ≈ $15.79 Million |
Dkr-35.62 Million ≈ $-5.57 Million |
-0.353x | +85.15% |
| 2019-12-31 | Dkr25.32 Million ≈ $3.96 Million |
Dkr-60.16 Million ≈ $-9.41 Million |
-2.376x | -251.29% |
| 2018-12-31 | Dkr56.20 Million ≈ $8.79 Million |
Dkr-38.01 Million ≈ $-5.95 Million |
-0.676x | -28.99% |
| 2017-12-31 | Dkr56.07 Million ≈ $8.77 Million |
Dkr-29.40 Million ≈ $-4.60 Million |
-0.524x | -18.13% |
| 2016-12-31 | Dkr44.29 Million ≈ $6.93 Million |
Dkr-19.66 Million ≈ $-3.08 Million |
-0.444x | -19.14% |
| 2015-12-31 | Dkr44.48 Million ≈ $6.96 Million |
Dkr-16.57 Million ≈ $-2.59 Million |
-0.373x | +33.77% |
| 2014-12-31 | Dkr28.69 Million ≈ $4.49 Million |
Dkr-16.14 Million ≈ $-2.52 Million |
-0.563x | -44.91% |
| 2013-12-31 | Dkr42.86 Million ≈ $6.71 Million |
Dkr-16.64 Million ≈ $-2.60 Million |
-0.388x | -102.92% |
| 2012-12-31 | Dkr-1.15 Million ≈ $-179.93K |
Dkr-15.28 Million ≈ $-2.39 Million |
13.287x | +484.76% |
| 2011-12-31 | Dkr3.94 Million ≈ $616.44K |
Dkr-13.61 Million ≈ $-2.13 Million |
-3.453x | +14.59% |
| 2010-12-31 | Dkr3.31 Million ≈ $517.72K |
Dkr-13.38 Million ≈ $-2.09 Million |
-4.043x | -368.99% |
| 2009-12-31 | Dkr15.41 Million ≈ $2.41 Million |
Dkr-13.29 Million ≈ $-2.08 Million |
-0.862x | +2.57% |
| 2008-12-31 | Dkr15.50 Million ≈ $2.43 Million |
Dkr-13.72 Million ≈ $-2.15 Million |
-0.885x | -84.47% |
| 2007-12-31 | Dkr29.45 Million ≈ $4.61 Million |
Dkr-14.13 Million ≈ $-2.21 Million |
-0.480x | -62897.70% |
| 2006-12-31 | Dkr-17.62 Million ≈ $-2.76 Million |
Dkr-13.46K ≈ $-2.11K |
0.001x | -83.18% |
| 2005-12-31 | Dkr-3.06 Million ≈ $-478.13K |
Dkr-13.88K ≈ $-2.17K |
0.005x | -99.19% |
| 2000-12-31 | Dkr894.00K ≈ $139.87K |
Dkr503.00K ≈ $78.70K |
0.563x | -- |
About BioPorto
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination o… Read more